Distribution of company announcements to the professional platforms, finance portals and syndication of important corporate news to a wide variety of news aggregators and financial news systems.
Lund, Sweden, November 11, 2008 - Alligator Bioscience, the protein optimization company, is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Wednesday, November 12, at 12:25 pm US Eastern Time /18:25 Central European Time, at the New York Palace Hotel in New York City, US. The presentation, given by Alligator's chief executive officer, Dr Gun-Britt Fransson, will provide an update on the company's protein optimization technology, FIND® and how it is exploited to build a competitive pipeline of discovery phase biopharmaceuticals. Selected discovery programs will also be disclosed: ADC-1001 a second generation IL-1 receptor antagonist and ADC-1004 a selective high potent C5aR antagonist.
About Alligator Bioscience AB Alligator Bioscience discovers and develops early protein drug candidates. The method used is the company' own patented FIND® technology (Fragment Induced Diversity). Established in 2001 in Lund, Sweden, the company currently has 23 employees. Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry and created an internal pipeline of therapeutic drug candidates. The areas of indication on which Alligator is focused are inflammatory diseases and cancer. Alligator Bioscience operates from the Ideon Science Park in Lund, Sweden. For further general information please visit www.alligatorbioscience.com.
Contacts: Alligator Bioscience AB Dr Gun-Britt Fransson, CEO Schelevägen 19A SE-223 70 Lund, Sweden Tel: +46 (0)46-2864280 Fax: +46 (0)46-2864290
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
